Target Name: CD59
NCBI ID: G966
Review Report on CD59 Target / Biomarker Content of Review Report on CD59 Target / Biomarker
CD59
Other Name(s): MIN2 | G344 | CD59 variant 5 | MEM43 | 20 kDa homologous restriction factor | MSK21 | CD59 variant 1 | T cell-activating protein | Ly-6-like protein | MAC-inhibitory protein | MACIF | EJ30 | EL32 | CD59 molecule, complement regulatory protein, transcript variant 3 | CD59 glycoprotein (isoform 2) | CD59 molecule, complement regulatory protein,, transcript variant 4 | CD59 variant 2 | CD59 glycoprotein | Lymphocytic antigen CD59/MEM43 | CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344) | 1F5 antigen | CD59 molecule, complement regulatory protein, transcript variant 1 | membrane inhibitor of reactive lysis | PROTECTIN | Surface anitgen recognized by monoclonal antibody 16.3A5 | CD59 molecule, complement regulatory protein, transcript variant 5 | CD59 molecule, complement regulatory protein, transcript variant 6 | MIN1 | membrane attack complex inhibition factor | CD59 antigen | EJ16 | CD59 blood group antigen | membrane attack complex (MAC) inhibition factor | MEM43 antigen | human leukocyte antigen MIC11 | Membrane attack complex (MAC) inhibition factor | CD59 molecule, complement regulatory protein, transcript variant 8 | lymphocytic antigen CD59/MEM43 | 16.3A5 | HRF-20 | MAC-IP | Membrane inhibitor of reactive lysis | MIRL | CD59 molecule, complement regulatory protein, transcript variant 7 | protectin | CD59 variant 6 | Membrane attack complex inhibition factor | p18-20 | CD59 variant 4 | CD59 variant 8 | CD59 variant 3 | CD59 molecule (CD59 blood group) | Human leukocyte antigen MIC11 | CD59 variant 7 | 1F5 | MIC11 | Protectin | CD59_HUMAN | CD59 molecule, complement regulatory protein | CD59 molecule, complement regulatory protein, transcript variant 2 | MIN3 | HRF20 | surface anitgen recognized by monoclonal antibody 16.3A5

CD59 (MIN2) as a Potential Drug Target and Biomarker: Implications for Cancer Treatment

CD59 (Min2) is a protein that is expressed in various tissues, including the liver, spleen, and lymphoid organs. It is a member of the immunoglobulin superfamily and has been implicated in immune surveillance and regulation. Several studies have suggested that CD59 may have potential as a drug target or biomarker for cancer treatment. In this article, we will explore the potential of CD59 as a drug target and biomarker for cancer treatment.

CD59 as a Drug Target

CD59 has been shown to play a critical role in the immune response and has been implicated in the regulation of T cell responses. Several studies have suggested that CD59 may be a potential drug target for cancer treatment. One of the main reasons for this is that CD59 has been shown to be expressed in various types of cancer, including lung cancer, breast cancer, and colon cancer. Additionally, several studies have shown that targeting CD59 with drugs can lead to significant improvements in cancer outcomes, including increased response rates and reduced toxicity.

One of the most promising CD59 drug targets is the PD-1/PD-L1 interface. PD-1 is a protein that is expressed in various types of cancer and has been shown to play a critical role in the immune response. PD-L1 is a protein that is expressed in various types of cancer and has been shown to interact with PD-1 and promote the growth and survival of cancer cells. By targeting the PD-1/PD-L1 interface, drugs have been shown to be effective in treating various types of cancer.

Another potential CD59 drug target is the Fc portion of the immunoglobulin molecule. The Fc portion of the immunoglobulin molecule is a portion of the protein that is responsible for binding to antigens and triggering the immune response. Several studies have shown that targeting the Fc portion of the immunoglobulin molecule with drugs can be effective in treating various types of cancer.

CD59 as a Biomarker

In addition to its potential as a drug target, CD59 has also been shown to be a potential biomarker for cancer treatment. Several studies have shown that measuring the level of CD59 in cancer cells can be an effective way to predict the response to certain types of cancer treatment. For example, one study showed that measuring the level of CD59 in breast cancer cells before and after treatment with a specific drug showed that the level of CD59 decreased significantly in the treated cells, which suggests that the drug was effective in targeting the CD59 protein.

Another study showed that measuring the level of CD59 in lung cancer cells before and after treatment with a specific drug showed that the level of CD59 decreased significantly in the treated cells, which suggests that the drug was effective in targeting the CD59 protein.

Conclusion

In conclusion, CD59 has been shown to play a critical role in the immune response and has been implicated in the regulation of T cell responses. Several studies have suggested that CD59 may be a potential drug target for cancer treatment. The PD-1/PD-L1 interface and the Fc portion of the immunoglobulin molecule are two potential targets for CD59. Additionally, CD59 has also been shown to be a potential biomarker for cancer treatment, as it can be used to predict the response to certain types of cancer treatment. Further research is needed to fully understand the potential of CD59 as a drug target and biomarker for cancer treatment.

Protein Name: CD59 Molecule (CD59 Blood Group)

Functions: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase

The "CD59 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD59 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6